Baseline Demographics and Characteristics From a Paliperidone Palmitate Study in Subjects with Recent-Onset Schizophrenia or Schizophreniform Disorder

Benzer Materyaller

• SA12. Baseline Demographics and Clinical Characteristics From a Prospective, Randomized, Open-Label Study of Paliperidone Palmitate Long-Acting Injection in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder
  Yazar:: Brown, Brianne, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
  Yazar:: Sliwa, Jennifer Kern, ve diğerleri
  Baskı/Yayın Bilgisi: (2012)
• Paliperidone Palmitate Once-Monthly Treatment in Recent Onset and Chronic Illness Patients With Schizoaffective Disorder
  Yazar:: Bossie, Cynthia A., ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• S32. EFFICACY AND SAFETY OF PALIPERIDONE PALMITATE ONCE-MONTHLY IN PATIENTS WITH SCHIZOPHRENIA WITH LOW, MODERATE, AND HIGH RECENT DISEASE ACTIVITY AT BASELINE
  Yazar:: Lynum, Karimah, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
  Yazar:: Zhang, Fan, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)